Semaglutide is a synthetically engineered analogue of human glucagon-like peptide-1 (GLP-1) that exerts its effects by activating the GLP-1 receptor. GLP-1 is an incretin hormone secreted by L cells located in the distal ileum and colon. The structure of semaglutide has been modified based on native GLP-1 to resist enzymatic degradation and to enable strong binding to serum albumin in the bloodstream. Activation of the GLP-1 receptor stimulates insulin secretion and suppresses glucagon release, thereby effectively regulating blood glucose levels. In addition, it delays gastric emptying and reduces appetite, contributing to body-weight control.
Aplicações de investigação:
-Type 2 diabetes treatment
-Weight management studies
-Cardiovascular risk reduction research
